149 related articles for article (PubMed ID: 11060720)
1. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.
Movsesian MA
Expert Opin Investig Drugs; 2000 May; 9(5):963-73. PubMed ID: 11060720
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
3. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
Endoh M
Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
[No Abstract] [Full Text] [Related]
4. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
5. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.
Movsesian MA; Alharethi R
Expert Opin Investig Drugs; 2002 Nov; 11(11):1529-36. PubMed ID: 12437500
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
9. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
Nadur NF; de Azevedo LL; Caruso L; Graebin CS; Lacerda RB; Kümmerle AE
Eur J Med Chem; 2021 Feb; 212():113123. PubMed ID: 33412421
[TBL] [Abstract][Full Text] [Related]
10. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider.
Movsesian MA
J Card Fail; 2003 Dec; 9(6):475-80. PubMed ID: 14966789
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy with PDE III inhibitor for heart failure].
Watanabe H; Kajimoto K; Kawana M
Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
[No Abstract] [Full Text] [Related]
12. Phosphodiesterase inhibitors. Do the risks outweight the benefits?
Andrews R; Cowley AJ
Drug Saf; 1993 Dec; 9(6):404-9. PubMed ID: 8129862
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
14. Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure.
Tarpey SB; Sawmiller DR; Kelly C; Thompson WJ; Townsley MI
Am J Physiol Lung Cell Mol Physiol; 2003 May; 284(5):L766-73. PubMed ID: 12676767
[TBL] [Abstract][Full Text] [Related]
15. [How to use PDE III inhibitors].
Goto Y
Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
[No Abstract] [Full Text] [Related]
16. Phosphodiesterase inhibition in heart failure.
Movsesian M; Stehlik J; Vandeput F; Bristow MR
Heart Fail Rev; 2009 Dec; 14(4):255-63. PubMed ID: 19096931
[TBL] [Abstract][Full Text] [Related]
17. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure.
Ding B; Abe JI; Wei H; Huang Q; Walsh RA; Molina CA; Zhao A; Sadoshima J; Blaxall BC; Berk BC; Yan C
Circulation; 2005 May; 111(19):2469-2476. PubMed ID: 15867171
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
Kim GE; Kass DA
Handb Exp Pharmacol; 2017; 243():249-269. PubMed ID: 27787716
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis.
Osinski MT; Schrör K
Biochem Pharmacol; 2000 Aug; 60(3):381-7. PubMed ID: 10856433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
